DUBs are a family of over a hundred proteases that play important roles in protein and cellular homeostasis, processes that are critical to normal cell function. Evidence suggests
For over a decade, fewer than 10% of clinical trials that enter Phase I achieve FDA approval. Too many new drug submissions receive a rejection letter, request for
The label update is effective immediately and based on results from the Phase 4 TOURMALINE study, which showed no statistically significant difference between the groups taking Veltassa with
The portfolio primarily consists of oral solutions with a few semi-solid products. For the 12 months ended March 2018, combined sales of the acquired products were in excess
As a diversified company with a robust generics business, Amneal is now the 5th largest generics business in the United States, with a growing, high-margin specialty franchise. Shares
The oral formulation of cobitolimod is a potential follow-on product to the topical formulation, which is currently being investigated in the CONDUCT study – a phase IIb dose
In its inaugural year, the Pathways program will support research projects focused on helping those living with substance use disorders (SUD), including those relating to the use of
monARC's multi-disciplinary team of drug developers and technology experts have built disease-specific patient network applications and online tools that prequalify and engage patients during protocol development prior to
Casma is pioneering novel strategies to boost autophagy to arrest or reverse the progression of rare genetic diseases and broader pathologies, including neurodegeneration. Autophagy is the natural process
Delian Capital led the investment round with participation from existing and new investors including OnKure management. The investment will help the company aggressively accelerate its research and development
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.